Videregen company

Videregen Limited operates as a regenerative medicine company. Videregen’s goal is to offer the world’s first commercially available organ replacement products to address the chronic shortage of organs for transplantation. Formed in 2011 as a spin-out from Northwick Park Institute of Medical Research in London, it uses its proprietary technology to produce biological scaffolds to which a patient’s own stem cells are added, creating a bespoke organ replacement. Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world’s first commercially available organ replacements for these conditions, reducing healthcare costs and improving the quality of life for patients.
Technology: Regenerative Medicine
Industry: Regenerative Medicine
Headquarters: Liverpool, Liverpool, United Kingdom
Founded Date: 7-3
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 4
Total Funding: £3.1M
Estimated Revenue: $10M to $50M
Last Funding Type: Series A

Visit Website
Register and Claim Ownership